Filed: November 30, 2017

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

CIPLA LTD., Petitioners,

v.

ABRAXIS BIOSCIENCE, LLC, Patent Owner.

Case IPR2018-00162 Patent 7,820,788

PATENT OWNER'S MANDATORY NOTICES



Abraxis BioScience, LLC, the Patent Owner, provides the following mandatory notices pursuant to 37 C.F.R. § 42.8.

I. REAL PARTY-IN-INTEREST

In accordance with 37 C.F.R. § 42.8(b)(1), Patent Owner identifies Abraxis Biosciences, LLC ("Abraxis") and Celgene Corporation ("Celgene") as real parties-in-interest. Celgene is a corporation organized and existing under the laws of the State of Delaware, having a principal place of business at 86 Morris Avenue, Summit, New Jersey 07901. Abraxis is a wholly owned subsidiary of Celgene. Abraxis, a corporation organized and existing under the laws of the State of Delaware, having a principal place of business at 11755 Wilshire Boulevard, 20th Floor, Los Angeles, California 90025, is the owner of all right, title and interest in U.S. Patent No. 7,820,788 ("the '788 Patent") by virtue of an assignment from the inventors, Neil P. Desai, Patrick Soon-Shiong, and Vuong Trieu. The Assignment was recorded on October 16, 2008 at Reel 021694, Frame 0568.

II. RELATED MATTERS

Pursuant to 37 C.F.R. § 42.8(b)(2), Patent Owner identifies the following:

A. Proceedings Before the USPTO Involving Related Patents

- The '788 Patent is the subject of IPR2017-01101 and IPR2018-00152.
- U.S. Patent No. 7,923,536 ("the '536 Patent"), which issued from U.S.



Application Serial No. 11/553,339, which issued as the '788 Patent. The '536 Patent is the subject of IPR2017-01103, IPR2018-00153, and IPR2018-00163.

U.S. Patent No. 8,138,229 ("the '229 Patent"), which issued from U.S.
Application Serial No. 12/910,693, is a continuation of U.S.
Application Serial No. 11/553,339, which issued as the '788 Patent.
The '229 Patent is the subject of IPR2017-01104, IPR2018-00151, and IPR2018-00164.

B. Litigations Involving the Patent-at-Issue

The '788 Patent is the subject of the following pending litigations:

- Abraxis Bioscience, LLC et al v. Actavis, LLC, 2:16-cv-09074-JMV-MF (D.N.J. April 6, 2016).
- Abraxis Bioscience, LLC et al v. Cipla Ltd., 2:16-cv-09074-JMV-MF (D.N.J. Dec. 7, 2016).

III. LEAD AND BACKUP COUNSEL AND SERVICE INFORMATION

In accordance with 37 C.F.R. §§ 42.8(b)(3), 42.8(b)(4), and 42.10(a), Patent Owner identifies the following lead and backup counsel and service information:

Lead counsel: Christopher J. Harnett (Reg. No. 35,538)

Jones Day

250 Vesey Street

New York, NY 10281-1047

Tel: (212) 326-3939 Fax: (212) 755-7306

Email: charnett@ionesdav.com



Backup counsel:

Anthony M. Insogna (Reg. No. 35,203)	Cary Miller, Ph.D. (Reg. No. 54,708)
Jones Day	Jones Day
4655 Executive Drive, Suite 1500	4655 Executive Drive, Suite 1500
San Diego, CA 92121-3134	San Diego, CA 92121-3134
Tel: (858) 314-1200	Tel: (858) 314-1200
Fax: (844) 345-3178	Fax: (844) 345-3178
Email: aminsogna@jonesday.com	Email: cmiller@jonesday.com
Lisamarie LoGiudice, Ph.D. (Reg. No.	F. Dominic Cerrito (Reg. No. 38,100)
71,047)	Quinn Emanuel Urquhart & Sullivan,
Jones Day	LLP
250 Vesey Street	51 Madison Avenue, 22nd Floor
New York, NY 10281-1047	New York, NY 10010
Tel: (212) 326-3939	Tel: (212) 849-7112
Fax: (212) 755-7306	Fax: (212) 849-7100
Email: llogiudice@jonesday.com	Email: nickcerrito@quinnemanuel.com
Andrew S. Chalson (pro hac vice)	Frank C. Calvosa (Reg. No. 69,064)
Quinn Emanuel Urquhart & Sullivan,	Quinn Emanuel Urquhart & Sullivan,
LLP	LLP
51 Madison Avenue, 22nd Floor	51 Madison Avenue, 22nd Floor
New York, NY 10010	New York, NY 10010
Tel: (212) 849-7112	Tel: (212) 849-7112
Fax: (212) 849-7100	Fax: (212) 849-7100
Email:	Email:
andrewchalson@quinnemanuel.com	frankcalvosa@quinnemanuel.com
	D : 1 C W' (I :)
J. Patrick Elsevier, Ph.D. (Reg. No.	Daniel C. Wiesner (pro hac vice)
44,668)	Quinn Emanuel Urquhart & Sullivan,
Celgene Corporation	LLP
Vice President Litigation	51 Madison Avenue, 22nd Floor
86 Morris Ave	New York, NY 10010
Summit, NJ 07901	Tel: (212) 849-7112
Tel: (908) 673-9000	Fax: (212) 849-7100
Email: <u>pelsevier@celgene.com</u>	Email:
	danielwiesner@quinnemanuel.com



Patent Owner consents to electronic service by email.

Respectfully submitted,

Dated: November 30, 2017 /s/Christopher J. Harnett

Christopher J. Harnett (Reg. No. 35,538)

Jones Day

250 Vesey Street

New York, NY 10281 Tel: (212) 326-3939 Fax: (212) 755-7306

Email: charnett@jonesday.com



DOCKET

Explore Litigation Insights



Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.

